Abstract
Objectives
To describe the 12-month outcomes of the Xen45 glaucoma stent.
Methods
Non-comparative retrospective study of all cases who underwent Xen glaucoma surgery in April 2017 or earlier and completed 12 months of follow-up. The primary outcome measures were intraocular pressure (IOP) reduction and number of glaucoma medications at 12 months postoperatively. The secondary outcome measures were surgical complications and the success rate of surgery at 1 year. Success rate was defined according to the multiple IOP thresholds of 15 mmHg, 18 mmHg, and 21 mmHg with all requiring a drop of 20% and no additional glaucoma surgery. Revision or needling of the Xen conjunctival bleb was not considered to constitute a surgical failure.
Results
Sixty-eight eyes were included in the study. Mean IOP dropped from 22.1 mmHg preoperatively to 14.8 mmHg at 12 months, a 33% drop (p < 0.0001). Mean number of glaucoma medications reduced from 2.9 preoperatively to 1.1 at 12 months (p < 0.0001). In total, 54.4% of cases were back on glaucoma medications by 12 months. Success rate varied from 32.4% when defined as IOP ≤ 15 mmHg and ≥ 6 mmHg and ≥ 20% reduction without medications to 70.6% when defined as IOP ≤ 21 mmHg and ≥ 6 mmHg and ≥ 20% reduction with or without medications. Thirty cases (44.1%) required bleb needling or surgical revision.
Conclusions
The Xen45 is effective at reducing IOP and glaucoma medication use at 12 months postoperatively. Patients considering this procedure should be warned that by 12 months postoperatively there is a significant chance of requiring postoperative bleb intervention and glaucoma drops.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Vinod K, Gedde SJ, Feuer WJ, et al. Practice preferences for glaucoma surgery: a survey of the American glaucoma Society. J Glaucoma. 2017;26:687–93.
Richter GM, Coleman AM. Minimally invasive glaucoma surgery: current status and future prospects. Clin Ophthalmol. 2016;10:189–206.
Lavia C, Dallorto L, Maule M, Ceccarelli M, Fea AM. Minimally-invasive glaucoma surgeries (MIGS) for open angle glaucoma: a systematic review and meta-analysis. PLoS ONE. 2017;12:e0183142.
Green W, Lind J, Sheybani A. Review of the Xen Gel Stent and InnFocus MicroShunt. Curr Opin Ophthalmol. 2018;29:162–70.
Sheybani A, Lenzhofer M, Hohensinn M, et al. Phacoemulsification combined with a new ab interno gel stent to treat open-angle glaucoma: pilot study. J Cataract Refract Surg. 2015;41:1905–9.
Sheybani A, Dick B, Ahmed IIK. Early clinical results of a novel ab interno gel stent for the surgical treatment of open-angle glaucoma. J Glaucoma. 2016;25:e691–e696.
Galal A, Bilgic A, Eltanamly R, et al. XEN glaucoma implant with mitomycin C 1-year follow-up: result and complications. J Ophthalmol. 2017:5457246.
Pérez-Torregrosa VT, Olate-Pérez Á, Cerdà-Ibáñez M, et al. Combined phacoemulsification and Xen45 surgery from temporal approach and 2 incisions. Arch Soc Esp Oftalmol. 2016;91:415–21.
De Gregoria A, Pedrotti E, Russo L, et al. Minimally invasive combined glaucoma and cataract surgery: clinical results of the smallest ab interno gel stent. Int Ophthalmol. 2018;38:1129–1134.
Tan SZ, Walkden A, Au L. One-year result of XEN45 implant for glaucoma: efficacy, safety, and postoperative management. Eye. 2018;32:324–32.
Hengerer FH, Kohnen T, Mueller M, Conrad-Hengerer I. Ab interno gel implant for the treatment of glaucoma patients with or without prior glaucoma surgery: 1-year results. J Glaucoma. 2017;26:1130–6.
Fea AM, Spinetta R, Cannizzo PML, et al. Evaluation of bleb morphology and reduction in IOP and glaucoma medication following implantation of a novel gel stent. J Ophthalmol. 2017:9364910.
Grover DS, Flynn WJ, Bashford KP, et al. Performance and safety of a new ab interno gelatin stent in refractory glaucoma at 12 months. Am J Ophthalmol. 2017;183:25–36.
Rodriguez‐Una I, Azuara‐Blanco A, King AJ. Survey of glaucoma surgical preferences and post‐operative care in the United Kingdom. Clin Exp Ophthalmol. 2017;45:232–40.
National Institute for Health and Clinical Excellence. Microinvasive subconjunctival insertion of a trans-scleral gelatin stent for primary open-angle glaucoma 2018. Available from: https://www.nice.org.uk/guidance/ipg612/chapter/1-Recommendations.
Gedde SJ, Feuer WJ, Shi W, et al. Treatment outcomes in the primary tube versus trabeculectomy study after 1 year of follow-up. Ophthalmology. 2018;125:650–63.
Armstrong JJ, Wasiuta T, Kiatos E, Malvankar-Mehta M, Hutnik CML. The effects of phacoemulsification on intraocular pressure and topical medication use in patients with glaucoma: a systematic review and meta-analysis of 3-year data. J Glaucoma. 2017;26:511–22.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All authors have received meeting sponsorship from Allergan Ophthalmology except CK. MS has received research funding from Allergan.
Additional information
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Smith, M., Charles, R., Abdel-Hay, A. et al. 1-year outcomes of the Xen45 glaucoma implant. Eye 33, 761–766 (2019). https://doi.org/10.1038/s41433-018-0310-1
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/s41433-018-0310-1
This article is cited by
-
Short-term efficacy and safety of A-stream glaucoma shunt: a 6-month study
Eye (2025)
-
Recanalization of Xen45 gel stent implant occlusion using 10 − 0 nylon suture in refractory glaucoma: a case report
BMC Ophthalmology (2023)
-
Complications and post-operative interventions in XEN45 gel stent implantation in the treatment of open angle glaucoma—a systematic review and meta-analysis
Eye (2023)
-
Glaucoma medical treatment as a predictor of XEN45 subconjunctival gel implant hypotensive efficacy
Graefe's Archive for Clinical and Experimental Ophthalmology (2023)
-
The efficacy of XEN gel stent implantation in glaucoma: a systematic review and meta-analysis
BMC Ophthalmology (2022)
